DOCSLIB.ORG

United States Patent (19) 11 Patent Number: 6,071,970 Mueller Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent (19) 11 Patent Number: 6,071,970 Mueller Et Al USOO607 1970A United States Patent (19) 11 Patent Number: 6,071,970 Mueller et al. (45) Date of Patent: Jun. 6, 2000 54) COMPOUNDS ACTIVE ATA NOVELSITE WOA 93 ON RECEPTOR-OPERATED CALCUM O4373 3/1993 WIPO. CHANNELS USEFUL FOR TREATMENT OF 9521612 8/1995 WIPO. NEUROLOGICAL DISORDERS AND 9605818 2/1996 WIPO. DISEASES 964OO97 12/1996 WIPO. OTHER PUBLICATIONS 75 Inventors: Alan L. Mueller, Salt Lake City; Manuel F. Balandrin, Sandy; Marcusson, Jan O., et al., “Inhibition of Hparoxetine Bradford C. VanWagenen, Salt Lake binding by various Serotonin uptake inhibitors: Structure City; Eric G. DelMar, Salt Lake City; activity-relationships”, European Journal of Pharmacol Scott T. Moe, Salt Lake City; Linda D. ogy, 215, 1992, 191-198. Artman, Salt Lake City; Robert M. Chemical Abstracts, vol. 69, 1968, p. 3322. Barmore, Salt Lake City, all of Utah Chemical Abstracts, vol. 67, 1967, p. 3059. Chemical Abstracts, vol. 66, 1967, p. 4375. 73 Assignee: NPS Pharmaceuticals, Inc., Salt Lake Chemical Abstracts, vol. 5, p. 423, 1959. City, Utah Williams, Ifenprodil Discriminates Subtypes of the N-meth yl-D-asparate Receptor: Selectivity and Mechanisms at 21 Appl. No.: 08/485,038 Recombinant Heteromeric Receptors, Mol. Pharmacol., 44: 851, 1993). 22 Filed: Jun. 7, 1995 Wiley and Balster, Preclinical Evaluation of N-Methyl D-aspartate Antagonists for Antianxiety Effects: a Review Related U.S. Application Data In: Multiple Sigma and PCP Receptor Ligands; Mechanisms 63 Continuation-in-part of application No. PCT/US94/12293, for Neuromodulation and Neuroprotection NPP Books, Ann Oct. 26, 1994, which is a continuation-in-part of application Arbor, Michigan pp. 801-815, 1992. No. 08/288,668, Aug. 9, 1994, abandoned, which is a Ginsberg and Busto, Rodent Models of Cerebral Ischemia, continuation-in-part of application No. 08/194.210, Feb. 8, Stroke, 20:1627, 1989. 1994, abandoned, which is a continuation-in-part of appli Karpiak et al., “Animal Models for the Study of Drugs in cation No. 08/014,813, Feb. 8, 1993, abandoned. Ischemic Stroke', Ann. Rev. Pharmacol. Toxicol, 29:403, 51) Int. Cl." ........................ A61K31/135; CO7C 211/03 1989. 52 U.S. Cl. .......................... 514/648; 514/183; 514/210; Willetts et al., “The Behavioral Pharmacology of NMDA 514/212; 514/315; 514/408; 514/428; 514/645; Receptor Antagonists' Trends Pharmacol. Sci., 11:423, 514/646; 514/653; 514/654; 564/315; 564/316; 1990. 564/319 Olney, et al., “Pathological Changes Induced in Cerebrocor 58 Field of Search ..................................... 514/645, 648, tical Neurons by Phencyclidine and Related Drugs”, Sci 514/183,210, 212, 408, 428, 315, 646, ence, 244: 1360, 1989. 653, 654; 564/315, 316, 319 Snell and Johnson, “In: Excitatory Amino Acids in Health and Disease”, John Wiley and Sons, p. 261, 1988. 56) References Cited Collingridge and Davis, In. The NMDA Receptor, IRL Press. p. 123, 1989. U.S. PATENT DOCUMENTS Rogawski, “Therapeutic Potential of Excitatory Amino Acid 3,372,193 3/1968 Moffett et al. .......................... 564/375 Antagonists: Channel Blockers and 2,3-benzodiazepines', 4,018,895 4/1977 Molloy et al. ... ... 514/651 Trends Pharmacol. Sci., 14:325, 1993. 4,313,896 2/1982 Molloy et al. ....... ... 564/347 Nason, et al., “Synthesis of Neurotoxic Nephila Spider 5,037,846 8/1991 Saccomano et al. .... ... 514/419 Venoms: NSTX-3 and JSTX-3”, Tetrahedron Lett., 5,145,870 9/1992 Jakobsen et al. ........ ... 514/524 30:2337, 1989. 5,185.369 2/1993 Saccomano et al. ... 514/5O2 Scatton et al., “NMDA Receptor Antagonists: Treatment for 5,310,756 5/1994 Jakobsen et al. ....................... 514/524 Brain Ischemia,” Drug News & Perspectives 4(2):89-95 FOREIGN PATENT DOCUMENTS (1991). 0 005 658 4/1979 European Pat. Off.. (List continued on next page.) 0208523 4/1986 European Pat. Off.. 0399.504 5/1990 European Pat. Off.. Primary Examiner Richard L. Raymond A 0436 332 7/1991 European Pat. Off.. Attorney, Agent, or Firm-Lyon & Lyon LLP 1051 281 2/1959 Germany. A300541 6/1964 Netherlands. 57 ABSTRACT A 33 285 12/1964 Netherlands. A 4239816 6/1994 Netherlands. Method and compositions for treating a patient having a 1 169944 7/1967 United Kingdom. neurological disease or disorder, Such as Stroke, head 1134715 11/1968 United Kingdom. trauma, Spinal cord injury, epilepsy, anxiety, or neurodegen 1135926 12/1968 United Kingdom. erative diseaseS Such as Alzheimer's Disease, Huntington's 9214709 3/1992 WIPO. WOA 93 Disease, Parkinson's Disease, or amyotrophic lateral Scle 04036 3/1993 WIPO. rosis (ALS). WOA 93 O4041 3/1993 WIPO. 185 Claims, No Drawings 6,071,970 Page 2 OTHER PUBLICATIONS Helke, C.J., et al., Antiextensor Effects of 3, 3-Diphenyl -n-Propylamine in Mouse, European Journal of Pharma Burtsev and Savkov, “Calcium Antagonists (Finoptin and cology, vol. 48, No. 3, 1978, pp. 231-235. Senzit) in the Treatment of Cerebrovascular Disorders,” Gisvold, S.E., et al., “Drug Therapy in Brain Eschaemia', Klinicheskaia Meditsina 67(9):51-54 (1989) (abstract from British Journal of Anesthesia, vol. 57, No. 1 1985, pp. Medline). 96-109. Cramer et al., “Kalinic Acid and 4-Aminopyridine Seizure Donevan et al. “GYKI 52466, A 2,3-Benzodiazepine, Is A Models in Mice: Evaluation of Efficacy of Anti-Epileptic Highly Selective, Noncompetitive Antagonist Of AMPA/ Agents and Calcium Antagonists,” Life Sciences Kainate Receptor Responses” 10 Neuron 51, 1993. 54:271-275 (1994). Nakanishi et al. “Bioorganic Studies Of Transmitter Recep Fingl and Woodbury, Chapter 1, pp. 1-46 in The Pharma tors With Philanthotoxin Analogs’ Pure & Applied Chem cological Basis of Therapeutics (5th edition),eds. Goodman istry vol. 66, #3 (1994). et al., MacMillan Publishing Co., Inc., New York (1975). Williams, “Effects Of Agelenopsis Aperta Toxins. On The Foye et al., Principals of Medicinal Chemistry, 4th edition, N-Methyl-D-Aspartate Receptor: Polyamine-Like And Lea & Febiger/Williams and Wilkins, Philadelphia, PA, pp. High-Affinity Antagonist Actions' 266 The Journal of 233,265,281–282,340–341, 418-427 and 430 (1995). Pharmacology and Experimental Therapeutics 231, 1993. Melloni et al., “Potential antidepressant agents. C-Aryloxy Deneris et al. “Pharmacological And Functional Diversity benzyl derivatives of ethanolamine and morpholine,” Eur: J. Of Neuronal Nicotinic Acetylcholine Receptors' 12 Trends Med. Chem.–Chim. Ther. 19:235–242 (1984). In Pharmacol. Sci. 34, 1991. The Merck Index, 11th edition, Merck & Co., Inc., Rahway, Fisher et al. “Evolving Toward Effective Therapy For Acute New Jersey, p. 218 at No. 1433, p. 337 at No. 2180, p. 623 Ischemic Stroke” 270 JAMA 360, 1993. at No. 3916, p. 655 at No. 4112, p. 1148 at No. 7198, p. 1227 Honoré et al. “Ouinoxalinediones: Potent Competitive Non at No. 7744, p. 1444 at No. 9098, and p. 1597 at No. 10024 NMDA Glutamate Receptor Antagonists' 24 Science 701, (1989). 1988. Mikio et al., “Synthesis of Analgesics,” Chemical Abstracts, Herlitz et al. “Argiotoxin Detects Molecular Differences. In vol. 83, No. 7, Aug. 18, 1975 at abstract No. XP002016632. AMPA Receptor Channels” 10 Neuron 1131, 1993. Palmer et al., “Anticonvulsant Properties of Calcium Chan Raditsch et al. “Subunit-Specific Block Of Cloned NMDA nel Blockers in Mice: N-Methyl-D-, L-Aspartate- and Bay Receptors By Argiotoxins 324 FEBS Lett. 63, 1993. K8644 Induced Convulsions are Potentially Blocked by the Reynolds, J.E.F., “Martindale, The Extra Pharmacopoeia, Dihydropyridines,” Epilepsia 34:372-380 (1993). The Pharmaceutical Press, London “Terolidine” 1989, pp. Paul et al., “Adaptation of the N-Methyl-D-Aspartate 543-544. Receptor Complex Following Chronic Antidepressant Treat Leszkovszky G., et al., “The Pharmacology of Diphenyla ments,” J. Pharmacology and Experimental Therapeutics lkyl Derivatives' Acta Physiologica Academiae Scientiarum 269: 95-102 (1994). Hungaricae, vol. 29, 1996, pp. 283–298. Prous, The Year'Drug News, Therapeutic Targets, 1995 Blake, J.C., et al., 2-Methyl-3, Edition, Prous Science Publishers, Barcelona, Spain, pp. 13, 3-Diphenyl-3-Propanolamine (2-MDP) Selectively 55-56, 58-59, 74, 89, 144-145, 152, 296-297 and 317 Antagonises N-Methyl-Aspartate (NMDA), Pharmacology (1995). Biochemistry cc Behavior, vol. 24, No. 1, 1986, pp. 23-25. Buschauer, A., et al., Synthesis and Histamine H2 agonistic Scatchard, “The Attractions of Proteins For Small Molecules activity of arpromidine Analogues: Replacement of the and Ions.” Ann. N.Y. Acad. Sci. 51:660-672 (1949). Pheniramine-like Moiety by Non-Heterocyclic Groups, Williams, “Effects of Agelenopsis Aperta Toxins on the Eur: J. Med. Chem, 1992 27:321-330. N-Methyl-D-Aspartate Receptor: Polamine-Like and Keasling, Hugh H., et al., “Central Nervous System Agents' High-Affinity Antagonists Actions,” J. Pharmacol. Exp. Journal of Medicinal Chemistry, 1971, vol. 14, No. 11, pp. Therap. 266:231 (1993). 1106–1111. Chemical Abstracts Service, Registry Handbook, Reg. No. Beckett, A.H., et al., “Configurational Studies in Synthetic 114272-62-7 through 116231-28-8,(1988)Supplement. Analgesics”,J. Chem. Soc., 900(1955). Chemical Abstract 54:24555i (1960), 24555-245556. Camps, Francisco, et al., “New and Efficient One-Pot Prepa Chemical Abstract 54:424a (1960). ration of Alkyl Halides From Alcohols', Communications, Sutton, K.G., et al. “Inhibition of Voltage-Activated CA2+ May 1987, pp. 511–512. Currents from Cultured Sensory Neurones By Spermine, Reist, E.J., et al., “Sodium Azide in Dimethylformamide for Argiotoxin-636 and a Synthetic Arginine Polyamine” the Preparation of Amino-Sugars”, Chemistry and Industry, Molecular Neuropharmacology, vol. 3, 1993, pp. 37-43. Oct. 13, 1962, pp. 1794–1795. Blagbrough, I.S., et al., “Polyamine Amide Toxins as Phar Moffett, R.B., et al., “Central Nervous System Agents”, macological Tools and Pharmaceutical agents, Proceedings Journal of Medicinal Chemistry, 1971, vol. 14, No. 11, pp. of the Royal Society of Edinburgh, vol. 99, No. 1-2, 1992, 1088–1111. pp. 67-81. Tang, A.H., et al., Phencyclidine-Like Behavioral Effects of Artman, L.D., et al., “Preferential Inhibitory Effects of 2-Methyl-3,3-diphenyl-3-propanolamine (2-MDP), Phar Arylamine Spider Toxins on NMDA Receptor-Mediated macology Biochemistry cc Behavior, vol.
Load more

Recommended publications
  • The Pharmacology of Autonomic Failure: from Hypotension to Hypertension
    1521-0081/69/1/53–62$25.00 http://dx.doi.org/10.1124/pr.115.012161 PHARMACOLOGICAL REVIEWS Pharmacol Rev 69:53–62, January 2017 Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: STEPHANIE W. WATTS The Pharmacology of Autonomic Failure: From Hypotension to Hypertension Italo Biaggioni Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee Abstract .....................................................................................53 I. Introduction . ...............................................................................54 A. Overview of Normal Cardiovascular Autonomic Regulation ...............................54 B. The Baroreflex . .........................................................................54 C. Pathophysiology of Orthostatic Hypotension and Autonomic Failure. ....................54 D. Ganglionic Blockade as a Pharmacological Probe To Understand Autonomic Failure.......55 E. Autonomic Failure as a Model To Understand Pathophysiology . ..........................55 II. Targeting Venous Compliance in the Treatment of Orthostatic Hypotension...................55 III. Pharmacology of Volume Expansion. .......................................................56 Downloaded from A. Fludrocortisone . .........................................................................56 B. Erythropoietin . .........................................................................56 IV. Replacing Noradrenergic Stimulation
    [Show full text]
  • Microneedle Device and Transdermal Administration Device Provided with Microneedles
    (19) & (11) EP 2 005 990 A9 (12) CORRECTED EUROPEAN PATENT APPLICATION published in accordance with Art. 153(4) EPC (15) Correction information: (51) Int Cl.: Corrected version no 1 (W1 A1) A61M 37/00 (2006.01) A61B 17/20 (2006.01) Corrections, see A61K 9/00 (2006.01) A61K 47/34 (2006.01) Search report Search Report replaced or added (86) International application number: PCT/JP2007/057737 (48) Corrigendum issued on: 29.07.2009 Bulletin 2009/31 (87) International publication number: WO 2007/116959 (18.10.2007 Gazette 2007/42) (43) Date of publication: 24.12.2008 Bulletin 2008/52 (21) Application number: 07741173.4 (22) Date of filing: 06.04.2007 (84) Designated Contracting States: • MATSUDO, Toshiyuki AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tsukuba-shi Ibaraki 305-0856 (JP) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • KUWAHARA, Tetsuji SI SK TR Tsukuba-shi Ibaraki 305-0856 (JP) (30) Priority: 07.04.2006 JP 2006106995 (74) Representative: Westendorp, Michael Oliver Splanemann Reitzner (71) Applicant: Hisamitsu Pharmaceutical Co., Inc. Baronetzky Westendorp Tosu-shi, Saga 841 (JP) Rumfordstrasse 7 D-80469 München (DE) (72) Inventors: • TOKUMOTO, Seiji Tsukuba-shi Ibaraki 305-0856 (JP) (54) MICRONEEDLE DEVICE AND TRANSDERMAL ADMINISTRATION DEVICE PROVIDED WITH MICRONEEDLES (57) The present invention provides a microneedle device having a coating, which is effective even with a low molecular weight active compound and can sustain the effect of the drug for a long period of time, and a transdermal drug administration apparatus with micro- needles.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Affinity Profiles of Hexahydro-Sila-Difenidol Analogues at Muscarinic Receptor Subtypes
    European Journal of Pharmacology, 168 (1989) 71-80 71 Elsevier EJP 50940 Affinity profiles of hexahydro-sila-difenidol analogues at muscarinic receptor subtypes 1 Günter Lambrecht *,Roland Feifel, Monika Wagner-Röder, Carsten Strohmann , 1 1 2 2 Harald Zilch , Reinhold Tacke , Magali Waelbroeck , Jean Christophe , Hendrikus Boddeke 3 and Ernst Mutschier Department of Pharmacology, University of Frankfurt, D-6000 Frankfurt/ M, F.R.G., 1 Institute of Jnorganic Chemistry, University of Karlsruhe, D-7500 Karlsruhe, F.R.G., 1 Department of Biochemistry and Nutrition, Medica/ Schoo/, Free University of Brussels, B-1000 Brussels, Belgium, and 1 Preclinical Research, Sandoz Ltd., CH-4002 Basel, Switzerland Received 20 Apri11989, accepted 13 June 1989 In an attempt to assess the structural requirements of hexahydro-sila-difenidol for potency and selectivity, a series of analogues modified in the amino group and the phenyl ring were investigated for their affinity to muscarinic M1- (rabbit vas deferens), Mr (guinea-pig atria) and Mr (guinea-pig ileum) receptors. All compounds were competitive antagonists in the three tissues. Their affinities to the three muscarinic receptor subtypes differed by more than two orders of magnitude and the observed receptor selectivities were not associated with high affinity. The pyrrolidino and hexamethyleneimino analogues, compounds substituted in the phenylring with a methoxy group or a chlorine atom as weil as p-fluoro-hexahydro-difenidol displayed the same affinity profile as the parent compound, hexahydro-sila-difen­ idol: M1 =M 3 > M 2 • A different selectivity patternwas observed for p-fluoro-hexahydro-sila-difenidol: M3 > M1 > M 2 • This compound exhibited its highest affinity for M3-receptors in guinea-pig ileum (pA 2 = 7.84), intermediate affinity for M1-receptors in rabbit vas deferens (pA 2 = 6.68) and lowest affinity for the Mrreceptors in guinea-pig atria (pA 2 = 6.01).
    [Show full text]
  • Pharmacokinetics of Oral Pridinol: Results of a Randomized, Crossover Bioequivalence Trial in Healthy Subjects
    International Journal of Clinical Pharmacology and Therapeutics, Vol. 59 – No. 6/2021 (471-477) Pharmacokinetics of oral pridinol: Results of a randomized, crossover bioequivalence trial in healthy subjects Original Maren Richter1, Frank Donath1, Ralph-Steven Wedemeyer2, André Warnke1, 3 3 ©2021 Dustri-Verlag Dr. K. Feistle Andreas Horstmann , and Claudia Peschel ISSN 0946-1965 DOI 10.5414/CP203900 1SocraTec R&D GmbH, Oberursel/Erfurt, 2SocraMetrics GmbH, Erfurt, and e-pub: April 9, 2021 3Strathmann GmbH & Co. KG, Hamburg, Germany Key words Abstract. Objectives: To establish the What is known about this subject bioavailability – bio- relative bioavailability and to assess bio- equivalence – immedi- equivalence of oral, immediate-release tab- – The anticholinergic agent pridinol has ate-release tablet – lets containing pridinol and to determine been used as a muscle relaxant for de- pharmacokinetics the pharmacokinetic properties of the com- cades. – pridinol pound. Methods and materials: In this single- – However, the published literature on the center, open-label, randomized, crossover pharmacology of pridinol is sparse. trial, healthy male and female adult subjects received single doses of the test and refer- – More accessible information on the cha- ence product containing 4 mg pridinol me- racteristics of pridinol, e.g., its pharma- sylate (equivalent to 3 mg pridinol) each cokinetics in humans, is needed. under fasting conditions. For pharmacoki- netic evaluation, blood samples were with- What this study adds drawn until 72 hours post dose. Pridinol in plasma was quantified by validated liquid – This is the first detailed report on the chromatography-mass spectrometry/mass pharmacokinetic properties of pridinol in spectrometry (LC-MS/MS). Adverse events humans, assisting the prescriber to make (AEs) were analyzed descriptively.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Nicotinic Ach Receptors
    Nicotinic ACh Receptors Susan Wonnacott and Jacques Barik Department of Biology and Biochemistry, University of Bath, Bath BA2 7AY, UK Susan Wonnacott is Professor of Neuroscience in the Department of Biology and Biochemistry at the University of Bath. Her research focuses on understanding the roles of nicotinic acetylcholine receptors in the mammalian brain and the molecular and cellular events initiated by acute and chronic nicotinic receptor stimulation. Jacques Barik was a PhD student in the Bath group and is continuing in addiction research at the Collège de France in Paris. Introduction and there followed detailed studies of the properties The nicotinic acetylcholine receptor (nAChR) is the of nAChRs mediating synaptic transmission at prototype of the cys-loop family of ligand-gated ion these sites. nAChRs at the muscle endplate and in sympathetic ganglia could be distinguished channels (LGIC) that also includes GABAA, GABAC, by their respective preferences for C10 and C6 glycine, 5-HT3 receptors, and invertebrate glutamate-, histamine-, and 5-HT-gated chloride channels.1,2 polymethylene bistrimethylammonium compounds, 7 nAChRs in skeletal muscle have been characterised notably decamethonium and hexamethonium. This DRIVING RESEARCH FURTHER in detail whereas mammalian neuronal nAChRs provided the first evidence that muscle and neuronal DRIVING RESEARCH FURTHER in the central nervous system have more recently nAChRs are structurally different. become the focus of intense research efforts. This In the 1970s, elucidation of the structure and function was fuelled by the realisation that nAChRs in the brain of the muscle nAChR, using biochemical approaches, and spinal cord are potential therapeutic targets for was facilitated by the abundance of nicotinic synapses a range of neurological and psychiatric conditions.
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • Solubilization of the Muscarinic Acetylcholine Receptor by I Sodium Cholate: Stabilization of the Receptor by Muscarinic Hgands
    \ i Biomedical Research 3 (6) 695-698, 1982 Solubilization of the muscarinic acetylcholine receptor by I sodium cholate: Stabilization of the receptor by muscarinic Hgands TATSUYA HAGA, TOSHIHIDE NUKADA and KAZUKO HAGA Department of Biochemistry, Hamamatsu University School of Medicine, Hamamatsu 431-31, Japan ABSTRACT Forty to fifty percent of the muscarinic receptor in membrane preparations of porcine caudate nucleus was solubilized by sodium cholate in its active form when the mem- branes were pretreated with carbamylcholine or other muscarinic ligands. The binding activity of solubilized receptors was assayed by using [3H]quinuclidinylben- zylate ([3H]QNB) after removal of cholate and carbamylcholine. Without the pre- treatment, sodium cholate abolished most of the binding activity. The solubilized receptor had a high afiinity for [3H]QNB with a dissociation constant of 58 pM and an affinity for muscarinic ligands similar to that of the membrane receptor. The muscarinic receptor has been studied in —80°C until use. In the standard procedure of detail with respect to its binding with muscarinic solubilization, the microsomal preparation ligands by using [3H]-labeled ligands (3, 12) and (about 5 mg protein per ml) was incubated with several subclasses with different affinities for l0 mM carbamylcholine in 50 mM Tris-HCI agonists (2) or selective antagonists (8) have buffer (pH 7.5) at 30°C for 10 min, then a half been reported. It is not known, however, volume of 3 ‘X, sodium cholate in the Tris buffer whether these subclasses represent several types was added and the incubation continued for 5 of receptors which differ as chemical entities, or min at 30°C.
    [Show full text]
  • Predicting Therapeutic and Aggravating Drugs for Hepatocellular Carcinoma Based on Tissue- Specific Pathways
    Predicting therapeutic and aggravating drugs for hepatocellular carcinoma based on tissue- specific pathways Liang Yu1*, Fengdan Xu1, Lin Gao1 1School of Computer Science and Technology, Xidian University, Xi’an, PR China Associate Editor: Liang Yu *Corresponding author E-mail: [email protected](LY) Abstract Motivation: Hepatocellular carcinoma (HCC) is a significant health problem worldwide and annual number of cases are nearly more than 700,000. However,there are few safe and effective therapeutic options for HCC patients.Here, we propose a new approach for predicting therapeutic and aggravating drugs for HCCbased ontissue-specificpathways, which considersnot onlyliver tissueand functional in- formationof pathways, but also the changes of single gene in pathways. Results: Firstly, we map genes related to HCC to the liver-specific protein interaction network and get anextended tissue-specific gene set of HCC. Then, based on the extended gene set, 12 enriched KEGGfunctional pathways are extracted.Using Kolmogorov–Smirnov statistic, we calculate the thera- peutic scores of drugs based on the 12 tissue-specific pathways. Finally, after filtering by Comparative Toxicogenomics Database (CTD) benchmark,we get 3 therapeutic drugs and 3 aggravating drugs for HCC. Furthermore, we validate the6potentially related drugs of HCC by analyzingtheiroverlaps with drug indications reported in PubMed literatures, and also making CMapprofile similarity analysis and KEGG enrichment analysis based on their targets. All analysis results suggest thatour approach is effective and accurate for discovering novel therapeutic options for HCC and it can be easily extended to other diseases.More importantly, our method can clearly distinguish therapeutic and aggravating drugsforHCC, which also can be used to indicateunmarked drug-disease associations in CTD as pos- itive or negative.
    [Show full text]
  • Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes
    0022-3565/01/2972-646–656$3.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 297, No. 2 Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics 3541/898983 JPET 297:646–656, 2001 Printed in U.S.A. Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes ROGER L. PAPKE, PAUL R. SANBERG, and R. DOUGLAS SHYTLE Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Florida (R.L.P.); and Departments of Neurosurgery and Psychiatry and the Neuroscience Program, University of South Florida College of Medicine, Tampa, Florida (P.R.S., D.S.) Received November 9, 2000; accepted for publication January 23, 2001 This paper is available online at http://jpet.aspetjournals.org ABSTRACT Downloaded from Because mecamylamine, a nicotinic receptor antagonist, is hibited by higher micromolar concentrations. Mecamylamine used so often in nicotine research and because mecamylamine inhibition of neuronal nAChR was noncompetitive and voltage may have important therapeutic properties clinically, it is im- dependent. Although there was little difference between S-(ϩ)- portant to fully explore and understand its pharmacology. In the mecamylamine and R-(Ϫ)-mecamylamine in terms of 50% in- present study, the efficacy and potency of mecamylamine and hibition concentration values for a given receptor subtype, its stereoisomers were evaluated as inhibitors of human ␣3␤4, there appeared to be significant differences in the off-rates for ␣3␤2, ␣7, and ␣4␤2 nicotinic acetylcholine receptors (nAChRs), the mecamylamine isomers from the receptors. Specifically, jpet.aspetjournals.org as well as mouse adult type muscle nAChRs and rat N-methyl- S-(ϩ)-mecamylamine appeared to dissociate more slowly from D-aspartate (NMDA) receptors expressed in Xenopus oocytes.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]